Neuroendocrine responses to apomorphine in depressed patients and healthy control subjects. 1984

D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney

Increasing evidence implicates altered dopamine function in major affective illness. In the present study, growth hormone responses to the dopamine agonist apomorphine were not different for 14 male depressed patients and 16 healthy male volunteers. Baseline and post-apomorphine prolactin levels were lower for the depressed patients than the control subjects, but the percent decrease following apomorphine was not different for the two groups. Neuroendocrine responses were not significantly altered during chronic treatment with the dopamine agonist piribedil. These neuroendocrine results suggest that decreased baseline prolactin levels in depressed patients do not reflect altered postsynaptic receptor sensitivity in the tuberoinfundibular dopamine system.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010891 Piribedil A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist. Piribendyl,ET-495,EU-4200,Piribedil Hydrochloride,Piribedil Mesylate,Piribedil Mono-hydrochloride,Trivastal,ET 495,ET495,EU 4200,EU4200,Hydrochloride, Piribedil,Mesylate, Piribedil,Mono-hydrochloride, Piribedil,Piribedil Mono hydrochloride
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D001058 Apomorphine A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use. Apokinon,Apomorphin-Teclapharm,Apomorphine Chloride,Apomorphine Hydrochloride,Apomorphine Hydrochloride Anhydrous,Apomorphine Hydrochloride, Anhydrous,Apomorphine Hydrochloride, Hemihydrate,Britaject,Apomorphin Teclapharm

Related Publications

D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney
November 1994, The American journal of psychiatry,
D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney
November 1996, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney
September 1992, The American journal of psychiatry,
D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney
November 1991, The American journal of psychiatry,
D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney
January 1983, Acta psychiatrica Scandinavica,
D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney
September 1991, The Journal of clinical endocrinology and metabolism,
D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney
May 1990, Journal of affective disorders,
D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney
May 1996, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney
March 1982, The British journal of psychiatry : the journal of mental science,
D C Jimerson, and N R Cutler, and R M Post, and A Rey, and P W Gold, and G M Brown, and W E Bunney
June 1984, The American journal of psychiatry,
Copied contents to your clipboard!